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Abstract This retrospective study of 432 patients was
conducted between 2000 and 2009 to compare immunosup-
pressive therapy responses in uveitis accompanied or unac-
companied by rheumatic diseases. We divided patients into
two groups: uveitis related or unrelated to rheumatic dis-
eases. The clinical improvement after treatment was mea-
sured at the end of the observation period. Of the 432
patients with uveitis, 33 (7.6%) patients suVered from asso-
ciated rheumatic diseases and 399 (92.4%) patients did not.
The groups showed similar clinical features, but the mean
age at onset of uveitis was lower in the rheumatic disease
group (44.06 § 2.13 years vs. 48.23 § 0.81 years). The
rheumatic diseases included spondyloarthropathy (31%),
Behcet’s disease (27%), rheumatoid arthritis (18%), sys-
temic lupus erythematosus (15%), Sjogren’s syndrome
(6%), and mixed connective tissue disease (3%). Erythro-
cyte sedimentation rate and C-reactive protein level were
increased in uveitis associated with rheumatic diseases,
whereas ocular complications were not. The response to
immunosuppressive therapy was signiWcantly increased in
cases of uveitis associated with rheumatic diseases
(P < 0.05). Therefore, during early treatment, uveitis accom-
panied by rheumatic diseases showed better response to
immunosuppressive therapy and less frequent complications.
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Introduction
The eye is often overlooked by rheumatologists. Anatomi-
cally, the uvea is the middle layer of the eye, sandwiched
between the sclera on the outside and the retina on the
inside. The anterior uvea consists of the iris, which forms
the pupil, and the ciliary body where aqueous humor is syn-
thesized. The posterior uvea is the choroid, a richly vascu-
lar tissue adjacent to the retina. Subsets of uveitis can be
anatomically deWned, as follows: iritis, iridocyclitis, cho-
roiditis, chorioretinitis, and panuveitis [1, 2].
The uveal inXammation can result from a condition
which involves the eye alone or can be caused by a variety
of systemic infections, such as toxoplasmosis and herpes
simplex. Anterior uveitis is among the common manifesta-
tions of eye disease in patients with seronegative spond-
yloarthropathy [3]. Information regarding the frequency of
uveitis associated with adult rheumatic inXammatory auto-
immune disease largely originates from ophthalmology
departments of tertiary hospitals where 9–40% of uveitis
was associated with adult rheumatic inXammatory autoim-
mune disease [4–6]. In the majority of cases, uveitis is
acute, with symptoms duration of less than 3 months and
good prognosis. In chronic and recurrent cases, however,
visual acuity may be impaired due to several complications,
such as cataract, secondary glaucoma, or cystoid macular
edema. In western countries, it has been estimated that uve-
itis causes about 5% of blindness [7]. Due to increasing life
expectancy, the proportion of senile degenerative condi-
tions as a cause of blindness will likely continue to increase
and, correspondingly, the share of most other conditions,
including uveitis, decreases, particularly in incidence
series. Nevertheless, scarce information is available on the
relative importance of diVerent uveitis entities as a cause of
visual impairment [8, 9].
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3904 Rheumatol Int (2012) 32:3903–3908Uveitis may present as a simple single disease, as well as
a complicated disease related to various systemic disorders.
Thus, uveitis may be considered as unexplained if the oph-
thalmologist did not detect systemic involvement at the
time of initial manifestation. In some patients, uveitis is
associated with infection and parasitic disease, depending
on geographic location, race, and climate [10–14].
The aim of this study was to describe the frequency of
uveitis associated with rheumatic inXammatory autoimmune
disease in adult patients seen in the rheumatology department
in a tertiary hospital in Busan, Korea, and to compare with
uveitis unaccompanied by rheumatic disease in their clinical
characteristics, treatment response, and eye complications.
Patients and methods
This observational study was conducted in 432 patients
diagnosed with uveitis who visited the rheumatologic
department for the evaluation of rheumatic disease,
between 2000 and 2009. The diagnosis of uveitis was
established in patients who met the diagnostic criteria of the
International Uveitis Study Group (IUSG) certiWed in the
Uveitis Section of the Ophthalmology Department, and
who, in addition, were diagnosed with rheumatic inXamma-
tory autoimmune disease that fulWlled the accepted classiW-
cation criteria [15, 16]. Excluded from the study were
records from foreign patients, patients with degenerative
rheumatic diseases and metabolic diseases, and patients
with uveitis caused by other etiologies, such as postopera-
tive uveitis, keratouveitis, and purulent infections.
The ocular disease diagnosed at the patient’s Wrst visit was
classiWed as anterior uveitis (iritis, iridocyclitis), intermediate
uveitis (inXammation of peripheral retinal and pars plana of
the ciliary body), posterior uveitis (choroiditis, chorioretinitis),
or panuveitis (generalized inXammation of the whole uvea).
The patients were divided into two groups: patients suVering
from uveitis related to rheumatic diseases and patients diag-
nosed only with uveitis. All patients with rheumatic disease-
related uveitis underwent special tests and diagnostic work-
ups. These tests included antinuclear antibody (ANA), HLA-
B27, rheumatoid factor (RF), radiography of the sacroiliac
joints, gallium-67 whole body scintigraphy, conjunctival and
lacrimal gland biopsy, Mantoux test, and serum-speciWc anti-
parasitic and antiviral antibodies.
We used the American College of Rheumatology (ACR)
criteria for the diagnosis of rheumatic disease. The follow-
ing data were obtained from patients’ records: age, sex,
type of uveitis, and age at presentation of the Wrst episode
of uveitis. On the Wrst visit to the ophthalmologist, the type
of uveitis, erythrocyte sedimentation rate (ESR), and C-
reactive protein (CRP) were checked. At the Wnal ophthal-
mic evaluation, the ocular sequelae and response to treat-
ment were recorded. Data analysis was performed using the
chi-squared (2) test for statistical analysis, and P values
<0.05 were considered as statistically signiWcant. All statis-
tical analyses were performed using the SPSS software ver-
sion 11.0 (SPSS Inc., Chicago, IL, USA).
Results
Of the 432 patients diagnosed with uveitis, 33 (8.27%)
patients had rheumatic disease-related uveitis and 399
(91.73%) suVered only from uveitis. There was no signiWcant
diVerence between the groups in gender, mean age at onset,
body mass index, underlying medical diseases, smoking, and
alcohol intake. However, location of uveitis, the peak age at
onset of uveitis, the degree of systemic inXammation, detec-
tion of autoantibodies, and the response to immunosuppres-
sive treatment were diVerent between each subject.
Uveitis accompanied rheumatic disease
In our study, 33 (8.27%) patients showed uveitis related to
rheumatic disease. The most common rheumatic disease
associated with uveitis was ankylosing sponylitis (31%),
followed by Behcet’s disease (27%), rheumatic arthritis
(18%), SLE (15%), Sjögren syndrome (6%), and mixed
connective tissue disease (3%) (Fig. 1). The male to female
ratio in this group was 17/16 (52% men). The mean age
was 44.06 § 2.13 years, and the average body mass index
(BMI) was 22.32 § 0.88 kg/m2. In general, anterior uveitis
was more common than uveitis located at other sites; how-
ever, posterior uveitis was more common in this group,
compared with uveitis unrelated to rheumatic disease
(Table 1). The ESR and CRP levels were increased in this
group, and the diVerence was statistically signiWcant
(Table 2). There was statistically signiWcant diVerence in
the positivity of antinuclear antibody, cryoglobulin, and
HLA-B27, but the antineutrophil cytoplasmic antibody,
anti-double-strand DNA antibody, and rheumatoid factor
Fig. 1 Types of rheumatic diseases found to be related to uveitis123
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important treatment drug, and high dose of systemic steroid
therapy was applied in 22 (67%) patients. Combined cyclo-
sporine and topical steroid treatment was used in 20
patients (61%) (Table 3). The most frequent ocular compli-
cations were cataract and retinal vacuities; the incidence of
complications was lower than in the comparison group, but
the diVerence was not statistically signiWcant (Table 4).
Uveitis unaccompanied rheumatic disease
In our study, 399 (91.73%) patients were diagnosed with
uveitis not associated with rheumatic disease. The age
ranged from 10 to 70 years, and many elderly patients
(aged over 60 years) were in this group (Fig. 2). The male
to female ratio was 211/188 (53% men). The mean age was
48.23 § 0.80 years, and the average BMI was
23.56 § 0.27 kg/m2. Diabetes mellitus and hypertension
were the most common comorbid conditions, and the most
common location was anterior uveitis (Table 1). The ESR
and CRP levels were lower than in uveitis associated with
rheumatic disease. There was no diVerence in positivity of
antinuclear antibody, antinuclear cytoplasmic antibody, and
cryoglobulin, compared to the other group (Table 2). High-
dose steroid therapy was used in 150 patients (38%), and
the immunosuppressive drug cyclosporine was used in 29
patients (7.3%). Combined topical and systemic steroid
treatment was conducted in 183 patients (46%), as pre-
sented in Table 3. The most frequent ocular compilations
were cystoid macular edema, cataract, retinal vasculitis,
optic neuritis, and glaucoma. The incidence of ocular com-
plications was higher than in the other group, but the diVer-
ence was not statistically signiWcant (Table 4).
Discussion
Eye inXammation may be a prominent feature of several
rheumatic diseases, such as spondyloarthropathy and Beh-
cet’s disease; therefore, some ophthalmologist focused
mainly on rheumatic disease as a cause of uveitis [11–13].
Our objective in this study was to analyze the type of
rheumatic disease associated with uveitis and its relation-
ship with systemic inXammation, autoantibody, treatment
drugs, and incidence of ocular complications. This report
based on patient records shows that, in adults (aged over
16 years), uveitis was associated with various rheumatic
inXammatory autoimmune diseases. Infection as a cause of
uveitis was initially ruled out. Because of peripheral joint
pain and/or low-intensity back pain, asthenia, and ady-
namia, the patients were initially seen by a general practi-
tioner, who diagnosed infectious or allergic conjunctivitis,
Table 1 Demographic and clinical characteristics in the rheumatic
disease-related uveitis and simple uveitis groups
RD rheumatic disease, BMI body mass index, HT hypertension, DM






Sex Male: 17 (52%), Male: 211 (53%),




44.06 § 2.13 48.23 § 0.81
Total: n (%) 33 (100) 399 (100)
<10 0 (0) 0 (0)
10–19 0 (0) 15 (3.8)
20–29 3 (9) 39 (3.8)
30–39 10 (30.3) 74 (8.5)
40–49 8 (24.2) 79 (19.8)
50–59 8 (24.2) 81 (20.3)
60–75 4 (12.1) 111 (27.8)
BMI (kg/m2) 22.32 § 0.880 23.56 § 0.271
Underlying diseases
HT 4 (12%) 64 (16%) 0.382
DM 1 (3%) 32 (8%) 0.272
HBV 2 (6.1%) 13 (3.3%) 0.315
HCV 1 (3%) 1 (0.3%) 0.147
Smoke 5 (18%) 77 (19%) 0.376
Alcohol 5 (18%) 72 (18%) 0.445
Location of uveitis
Anterior 14 (42%) 178 (45%) 0.478
Intermediate 5 (15%) 47 (12%) 0.364
Posterior 6 (18%) 27 (6.7%) 0.031
Panuveitis 8 (25%) 147 (36.3%) 0.102
Table 2 Information regarding association between autoantibody and
inXammatory markers in uveitis
ANA anti nuclear antibody, ANCA anti neutrophil cytoplasmic anti-
body, ESR erythrocyte sedimentation rate, CRP C-reactive protein
RD-related uveitis RD-unrelated uveitis P value
ANA 7 (21%) 32 (8%) 0.021
Anti-ds DNA 2 (6%) 4 (1%) 0.070
ANCA 1 (3%) 0 (0%) 0.076
Cryoglobulin 3 (9%) 4 (1%) 0.012
HLA B27 7 (21%) 22 (5.5%) 0.004
ESR > 20 12 (36.3%) 65 (16.3%) 0.007
ESR · 20 21 (63.4%) 334 (83.7%)
CRP > 0.5 10 (30.3%) 63 (15.8%) 0.035
CRP · 0.5 23 (69.7%) 336 (84.2%)
Total 33 399123
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nation by an ophthalmologist specialized in ocular inXam-
matory diseases. Upon the diagnosis of uveitis, the
ophthalmologist began treatment with topical steroids and
directed patients to the rheumatologist. Because of the large
number of patients being treated in the rheumatology out-
patient department, the delay to see the rheumatologist was
7–15 days. At the time of rheumatologic evaluation, extra-
ocular symptoms had disappeared and laboratory and
image studies were normal; thus, it was not usually possible
to establish the diagnosis of rheumatic inXammatory auto-
immune disease from the outset (or at Wrst episode of uve-
itis).
The cause of uveitis was unknown, but it usually follows
the mechanisms of action in which the eye is aVected by
autoimmune activation in up to 40% of cases. Thus, uveitis
is part of a multisystemic disease, rather than isolated,
organ-speciWc. In the future, some of the 60% idiopathic
cases might prove to be autoimmune in nature [17].
The anterior chamber response is characteristic of auto-
immune diseases, whereas the prevalence of infectious
causes is higher in posterior uveitis. In our study, anterior
uveitis was more common than posterior uveitis in both
groups. However, the uveitis related to rheumatic disease
was more common in posterior location than uveitis unre-
lated to rheumatic disease.
The mean age of patients was similar in the two groups,
but the onset age of uveitis associated with rheumatic dis-
ease was younger. The age distribution of patients in the
rheumatic disease-related uveitis group was 10–60 years,
but old-aged patients were more common than in uveitis
unrelated to rheumatic disease. Diabetes mellitus and
hypertension were the most common comorbid conditions
in uveitis unrelated to rheumatic disease.
Detection of elevated antinuclear antibodies (ANA) can
be useful for the positive diagnosis [18]. The positive
results of ANA, anti-ds DNA, ANCA, and HLA B27 show
the possibility of underlying rheumatic diseases. Therefore,
when a patient is diagnosed with uveitis, the patient should
Table 3 Combined steroid and 
immunosuppressive treatment in 
uveitis
RD-related uveitis RD-unrelated uveitis P value
Topical steroid Applied: 31 (94%)
Not applied: 2 (6%)
Applied: 314 (79%)
Not applied: 85 (21%)
0.022
Periocular steroid Applied: 10 (30%)
Not applied: 23 (70%)
Applied: 27 (6.8%)
Not applied: 372 (93.2%)
<0.000
Steroid treatment 0.018
High-dose oral steroid Applied: 22 (67%)
Not applied: 11 (33%)
Applied: 150 (38%)
Not applied: 249 (62%)
0.001
Immunosuppressive agent Applied: 23 (94%)
Not applied: 10 (6%)
Applied: 29 (7.3%)





Not applied: 13 (39%)
Applied: 183 (46%)
Not applied: 216 (54%)
0.074
Table 4 Information regarding association of the incidence of ocular
complications in the rheumatic disease-related uveitis and simple uve-
itis groups





































Fig. 2 The peak age of onset of rheumatic disease-related uveitis was
in the third, fourth, and Wfth decades, in 78.7% patients of our series
between 30 and 50 years of age. In contrast, the peak age of onset of
simple uveitis was over 60 years, showing that the prevalence of sim-
ple uveitis was proportionate with age123
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HLA-B27.
HLA associations have been observed in many types of
uveitis. Associations include HLA-B27 in acute anterior
uveitis, HLA-B51 in Behçet’s disease, and HLA-B44 in
occlusive vasculitis. A recent study in Behçet’s disease
patients showed that those with active uveitis had a signiW-
cant response to B27PD (a peptide derived from HLA-B27
with homology for HLA-B51), as compared with Behçet’s
disease patients without uveitis, or normal controls [19–
23]. Autoantibodies do not seem to play an active role in
the induction phase of the disease. Evidence for this is
derived from various sources. The study of human patho-
logic specimens reveals the presence of inWltrating CD4+,
but not B cells in the early phase of Behçet’s disease and
sarcoidosis. The presence of circulating immune complexes
in Behçet’s disease is associated with a better prognosis or
is a sign of good control by medication. These Wndings sug-
gest that antibodies in uveitis have a regulatory, or possibly
even a protective role. The presence of a suYcient level of
antibodies may even prevent recurrences, but this remains
to be demonstrated [24, 25].
The ESR and CRP levels represent systemic inXamma-
tion, and they were higher in uveitis associated with rheu-
matic disease. It showed that this type of uveitis was a
systemic inXammatory disease.
The decision of adequate therapy for patients with uve-
itis is diYcult because of the lack of guidelines and the pau-
city of randomized, controlled clinical trials. Treatment
decisions should include the compartment of inXammation.
Topical corticosteroid eye drops are reserved for anterior
uveitis. Periocular injections of steroid can be administered
if the inXammation is unilateral. Because of their better
penetration into the posterior ocular tissues, injections
should be considered in posterior uveitis, whereas topical
eye drops are usually eVective in anterior uveitis. In severe
bilateral intermediate or posterior uveitis, immunosuppres-
sive therapy is indicated. The drug of choice is high-dose
systemic corticosteroids, followed by slow tapering of dos-
age, with or without the addition of another immunosup-
pressive, steroid-sparing agent, such as methotrexate or
cyclosporine [26, 27]. Corticosteroids should be tapered
with close follow-up, rather than continuing prolonged top-
ical steroids, in an attempt to eliminate any sign of anterior
chamber reaction.
Recently, guidelines for the use of immunosuppressive
drugs for inXammatory eye disease were established and
include corticosteroids, azathioprine, methotrexate, myco-
phenolate mofetil, cyclosporine, tacrolimus, cyclophospha-
mide, and chlorambucil. Azathioprine and/or cyclosporine
are eVective in the management of ocular inXammation in
Behçet’s disease, as open-label trials suggest a high rate of
clinical response. Sulfasalazine was reported to ameliorate
the severity and prevent recurrences of anterior uveitis
associated with HLA B27 [28–30].
The incidence of ocular complications was lower in the
rheumatic disease-related uveitis group, although the diVer-
ence was not statistically signiWcant. It was inferred that
uveitis related to rheumatic disease was a more severe
inXammatory disease, so the response to immunosuppres-
sive therapy was more eVective in this group.
We believe that, in a patient diagnosed with uveitis, the
relationship with autoimmune disease should be considered
at early stage; consequently, rapid and appropriate applica-
tion of steroid and immunosuppressive agents in uveitis
associated with rheumatic disease could prevent ocular
complications. Future studies will be required to ascertain
the relationship between uveitis and rheumatic disease.
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